1. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Issue 4 (April 2019) Authors: Hofving, Tobias; Sandblom, Viktor; Arvidsson, Yvonne; Shubbar, Emman; Altiparmak, Gülay; Swanpalmer, John; Almobarak, Bilal; Elf, Anna-Karin; Johanson, Viktor; Elias, Erik; Kristiansson, Erik; Forssell-Aronsson, Eva; Nilsson, Ola Journal: Endocrine-related cancer Issue: Volume 26:Issue 4(2019) Page Start: 437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [OA164] Vandetanib may act as a radiosensitiser for 177Lu-octreotate treatment of medullary thyroid cancer. (August 2018) Authors: Sandblom, Viktor; Spetz, Johan; Shubbar, Emman; Ståhl, Ingun; Swanpalmer, John; Forssell-Aronsson, Eva Journal: Physica medica Issue: Volume 52(2018)Supplement 1 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion – A preclinical simulation of a novel treatment strategy. (June 2019) Authors: Sandblom, Viktor; Ståhl, Ingun; Hansson, Christoffer; Olofsson Bagge, Roger; Forssell-Aronsson, Eva Journal: Surgical oncology Issue: Volume 29(2019) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗